pregabalin zentiva
zentiva, k.s. - pregabalin - anxiety disorders; epilepsy - przeciwpadaczkowe narzędzia, - neuropathic pain , pregabalin zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , epilepsy , pregabalin zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , generalised anxiety disorder , pregabalin zentiva is indicated for the treatment of generalised anxiety disorder (gad) in adults.
biphozyl - roztwór do hemofiltracji i hemodializy
baxter holding b.v. - magnezu chlorek sześciowodny + sodu chlorek + sodu wodorowęglan + potasu chlorek + disodu fosforan dwuwodny - roztwór do hemofiltracji i hemodializy - -
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - leki immunosupresyjne - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
ibuvit d3 kids 15000 iu/ml krople doustne, roztwór
zakłady farmaceutyczne polpharma s.a. - cholecalciferolum - krople doustne, roztwór - 15000 iu/ml
levodril 60 mg/10 ml syrop
polfarmex s.a. - levodropropizinum - syrop - 60 mg/10 ml
optihepan 3 g/5 g granulat do sporządzania roztworu doustnego
natur produkt pharma sp. z o.o. - ornithini aspartas - granulat do sporządzania roztworu doustnego - 3 g/5 g
rivertaxo 10 mg tabletki powlekane
aflofarm farmacja polska sp. z o.o. - rivaroxabanum - tabletki powlekane - 10 mg
rivertaxo 20 mg tabletki powlekane
aflofarm farmacja polska sp. z o.o. - rivaroxabanum - tabletki powlekane - 20 mg
rivertaxo 15 mg tabletki powlekane
aflofarm farmacja polska sp. z o.o. - rivaroxabanum - tabletki powlekane - 15 mg